62 related articles for article (PubMed ID: 34892188)
1. Mathematical modeling of viral infection dynamics and immune response in SARS-CoV-2: A computational framework for testing drug efficacy.
Sharma S; Saxena A; Chel S; Mitra K; Giri L
Annu Int Conf IEEE Eng Med Biol Soc; 2021 Nov; 2021():4370-4373. PubMed ID: 34892188
[TBL] [Abstract][Full Text] [Related]
2. Computational simulations to dissect the cell immune response dynamics for severe and critical cases of SARS-CoV-2 infection.
Blanco-Rodríguez R; Du X; Hernández-Vargas E
Comput Methods Programs Biomed; 2021 Nov; 211():106412. PubMed ID: 34610492
[TBL] [Abstract][Full Text] [Related]
3. A multiscale multicellular spatiotemporal model of local influenza infection and immune response.
Sego TJ; Mochan ED; Ermentrout GB; Glazier JA
J Theor Biol; 2022 Jan; 532():110918. PubMed ID: 34592264
[TBL] [Abstract][Full Text] [Related]
4. Computational framework to understand the clinical stages of COVID-19 and visualization of time course for various treatment strategies.
Sharma S; Sarkar R; Mitra K; Giri L
Biotechnol Bioeng; 2023 Jun; 120(6):1640-1656. PubMed ID: 36810760
[TBL] [Abstract][Full Text] [Related]
5. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
[TBL] [Abstract][Full Text] [Related]
6. Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.
Selvaraj G; Kaliamurthi S; Peslherbe GH; Wei DQ
F1000Res; 2021; 10():127. PubMed ID: 33968364
[No Abstract] [Full Text] [Related]
7. Controls to Minimize Disruption of the Pharmaceutical Supply Chain During the COVID-19 Pandemic.
Cundell T; Guilfoyle D; Kreil TR; Sawant A
PDA J Pharm Sci Technol; 2020; 74(4):468-494. PubMed ID: 32467176
[TBL] [Abstract][Full Text] [Related]
8. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
9. Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening.
de Oliveira OV; Rocha GB; Paluch AS; Costa LT
J Biomol Struct Dyn; 2021 Jul; 39(11):3924-3933. PubMed ID: 32448085
[TBL] [Abstract][Full Text] [Related]
10. Modeling viral dynamics in SARS-CoV-2 infection based on differential equations and numerical analysis.
Odaka M; Inoue K
Heliyon; 2021 Oct; 7(10):e08207. PubMed ID: 34693064
[TBL] [Abstract][Full Text] [Related]
11. Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches.
Francés-Monerris A; Hognon C; Miclot T; García-Iriepa C; Iriepa I; Terenzi A; Grandemange S; Barone G; Marazzi M; Monari A
J Proteome Res; 2020 Nov; 19(11):4291-4315. PubMed ID: 33119313
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
13. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response.
Hattaf K; Yousfi N
Math Biosci Eng; 2020 Aug; 17(5):5326-5340. PubMed ID: 33120555
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
Selvaraj C; Dinesh DC; Panwar U; Abhirami R; Boura E; Singh SK
J Biomol Struct Dyn; 2021 Aug; 39(13):4582-4593. PubMed ID: 32567979
[TBL] [Abstract][Full Text] [Related]
16. Development of a novel mathematical model that explains SARS-CoV-2 infection dynamics in Caco-2 cells.
Staroverov V; Nersisyan S; Galatenko A; Alekseev D; Lukashevich S; Polyakov F; Anisimov N; Tonevitsky A
PeerJ; 2023; 11():e14828. PubMed ID: 36748087
[TBL] [Abstract][Full Text] [Related]
17. Within Host Dynamics of SARS-CoV-2 in Humans: Modeling Immune Responses and Antiviral Treatments.
Ghosh I
SN Comput Sci; 2021; 2(6):482. PubMed ID: 34661166
[TBL] [Abstract][Full Text] [Related]
18. Data-driven multi-scale mathematical modeling of SARS-CoV-2 infection reveals heterogeneity among COVID-19 patients.
Wang S; Hao M; Pan Z; Lei J; Zou X
PLoS Comput Biol; 2021 Nov; 17(11):e1009587. PubMed ID: 34818337
[TBL] [Abstract][Full Text] [Related]
19. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
20. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19.
Cantwell AM; Singh H; Platt M; Yu Y; Lin YH; Ikeno Y; Hubbard G; Xiang Y; Gonzalez-Juarbe N; Dube PH
J Virol; 2021 Sep; 95(20):e0101021. PubMed ID: 34319784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
